{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:49:06Z","timestamp":1792086546946,"version":"4.4.0"},"reference-count":36,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"2024 Nanjing Health Science and technology development special project","award":["ZKX24043"],"award-info":[{"award-number":["ZKX24043"]}]},{"name":"2024 Jiangsu Association of Chinese Medicine","award":["PDJH2024022"],"award-info":[{"award-number":["PDJH2024022"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>This study aims to systematically explore the potential molecular mechanism of Roburic Acid (RBA) in the treatment of Anaplastic Thyroid Carcinoma (ATC) through the approaches of network pharmacology, machine learning and in vitro experiments. Public databases were used to retrieve the potential targets of RBA and disease-related targets of ATC. Intersection analysis was performed to identify the common targets, followed by the construction of a Protein-Protein Interaction (PPI) network for these common targets. Enrichment analyses, including GO functional and KEGG pathway analyses, were carried out for the targets. Core targets were further prioritized using SVM, LASSO and random forest machine learning algorithms. Validation of the binding affinity and stability of RBA with the core target was performed using molecular docking and dynamics simulations. Finally, in vitro experiments\u2014including cell viability, scratch assay, apoptosis detection, and Western blot\u2014were conducted using the ATC cell line KHM-5M to validate the therapeutic effect and underlying mechanism of RBA. A total of 401 RBA-associated targets and 2151 ATC-related targets were identified; their intersection yielded 173 shared targets. GO enrichment analysis indicated that these targets were mainly involved in responses to peptide hormones and nuclear receptor activity, among other biological functions. KEGG pathway analysis showed significant enrichment in cancer-related pathways, including the PI3K-Akt and MAPK signaling pathways. Using SVM, LASSO regression, and random forest models, KIT was consistently identified as the single core target. Molecular docking and molecular dynamics simulations demonstrated strong binding between RBA and c-KIT, characterized by low binding energy and the formation of a stable protein-ligand complex. In vitro, RBA significantly reduced KHM-5M cell viability and migration; the inhibitory effect on migration became pronounced at 24 h and was comparable to that of the positive control DOX. Furthermore, RBA promoted apoptosis and dose-dependently suppressed c-KIT phosphorylation. This study integrated network pharmacology, machine learning, and molecular simulations to identify KIT as a high-confidence core target of RBA in ATC. Preliminary in vitro validation demonstrated that RBA suppresses ATC cell viability and migration, induces apoptosis, and inhibits c-KIT phosphorylation in a dose-dependent manner.<\/jats:p>","DOI":"10.1371\/journal.pone.0359087","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:29:49Z","timestamp":1792085389000},"page":"e0359087","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Network pharmacology and machine learning reveal kit as a target of roburic acid in anaplastic thyroid carcinoma: Preliminary in vitro validation"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-6992-6690","authenticated-orcid":true,"given":"Foxing","family":"Tan","sequence":"first","affiliation":[{"name":"Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine","place":["Jiangsu, Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haolin","family":"Du","sequence":"additional","affiliation":[{"name":"Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine","place":["Jiangsu, Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longcheng","family":"Deng","sequence":"additional","affiliation":[{"name":"Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine","place":["Jiangsu, Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaping","family":"Shen","sequence":"additional","affiliation":[{"name":"Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine","place":["Jiangsu, Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Yang","sequence":"additional","affiliation":[{"name":"Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine","place":["Jiangsu, Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Mei","sequence":"additional","affiliation":[{"name":"Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine","place":["Jiangsu, Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zilu","family":"Chen","sequence":"additional","affiliation":[{"name":"Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine","place":["Jiangsu, Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Huang","sequence":"additional","affiliation":[{"name":"Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine","place":["Jiangsu, Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,10,15]]},"reference":[{"issue":"13","key":"pone.0359087.ref001","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1001\/jama.2017.2719","article-title":"Trends in thyroid cancer incidence and mortality in the United States, 1974-2013","volume":"317","author":"H Lim","year":"2017","journal-title":"JAMA"},{"issue":"4","key":"pone.0359087.ref002","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1001\/jamaoto.2022.5045","article-title":"Association of treatment strategies and tumor characteristics with overall survival among patients with anaplastic thyroid cancer: A single-institution 21-year experience","volume":"149","author":"SS Wu","year":"2023","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"3","key":"pone.0359087.ref003","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1172\/JCI85271","article-title":"Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers","volume":"126","author":"I Landa","year":"2016","journal-title":"J Clin Invest"},{"key":"pone.0359087.ref004","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.semcancer.2020.01.005","article-title":"Molecular therapeutics for anaplastic thyroid cancer","volume":"61","author":"N Pozdeyev","year":"2020","journal-title":"Semin Cancer Biol"},{"key":"pone.0359087.ref005","doi-asserted-by":"crossref","unstructured":"Xu B, Fuchs T, Dogan S, Landa I, Katabi N, Fagin JA, et al. Dissecting anaplastic thyroid carcinoma: A comprehensive clinical, histologic, immunophenotypic, and molecular study of 360 cases. thyroid: Official journal of the American Thyroid Association. 2020;30(10):1505\u201317.","DOI":"10.1089\/thy.2020.0086"},{"issue":"1","key":"pone.0359087.ref006","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1038\/s41598-023-30162-5","article-title":"Comparison of clinicopathological characteristics and survival between symptomatic and asymptomatic anaplastic thyroid carcinoma","volume":"13","author":"S Cho","year":"2023","journal-title":"Sci Rep"},{"issue":"9","key":"pone.0359087.ref007","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1001\/jamaoncol.2020.3362","article-title":"Evaluation of overall survival in patients with anaplastic thyroid carcinoma, 2000-2019","volume":"6","author":"A Maniakas","year":"2020","journal-title":"JAMA oncology"},{"issue":"5","key":"pone.0359087.ref008","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1089\/thy.2016.0395","article-title":"Patterns of treatment failure in anaplastic thyroid carcinoma","volume":"27","author":"SN Rao","year":"2017","journal-title":"Thyroid"},{"issue":"5","key":"pone.0359087.ref009","doi-asserted-by":"crossref","first-page":"283","DOI":"10.5582\/bst.2021.01318","article-title":"The positive role of traditional Chinese medicine as an adjunctive therapy for cancer","volume":"15","author":"X Zhang","year":"2021","journal-title":"Biosci Trends"},{"key":"pone.0359087.ref010","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.2147\/IJN.S502104","article-title":"Harnessing the power of traditional chinese medicine in cancer treatment: The role of nanocarriers","volume":"20","author":"Z Fu","year":"2025","journal-title":"Int J Nanomedicine"},{"key":"pone.0359087.ref011","doi-asserted-by":"crossref","first-page":"1661503","DOI":"10.3389\/fphar.2025.1661503","article-title":"Efficacy and safety of traditional Chinese medicine (TCM) combined with immune checkpoint inhibitors (ICIs) for the treatment of cancer: A systematic review and meta-analysis","volume":"16","author":"Y Ke","year":"2025","journal-title":"Front Pharmacol"},{"key":"pone.0359087.ref012","doi-asserted-by":"crossref","first-page":"666368","DOI":"10.3389\/fphar.2021.666368","article-title":"Clinical application of chinese herbal injection for cancer care: Evidence-mapping of the systematic reviews, meta-analyses, and randomized controlled trials","volume":"12","author":"M Yang","year":"2021","journal-title":"Front Pharmacol"},{"issue":"33","key":"pone.0359087.ref013","doi-asserted-by":"crossref","first-page":"27096","DOI":"10.1039\/D5RA01244A","article-title":"A comparative chemical composition and main component content of various parts of Gentiana macrophylla Pall. by UPLC-Q-orbitrap MS and HPLC","volume":"15","author":"Q Mu","year":"2025","journal-title":"RSC Adv"},{"issue":"13","key":"pone.0359087.ref014","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26136420","article-title":"Anticancer activity of roburic acid: In vitro and in silico investigation","volume":"26","author":"A Gieleci\u0144ska","year":"2025","journal-title":"International Journal of Molecular Sciences"},{"issue":"1","key":"pone.0359087.ref015","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/s41392-023-01499-0","article-title":"Metabolic reprogramming of proinflammatory macrophages by target delivered roburic acid effectively ameliorates rheumatoid arthritis symptoms","volume":"8","author":"N Jia","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"pone.0359087.ref016","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1002\/jcp.30642","article-title":"Roburic acid attenuates osteoclastogenesis and bone resorption by targeting RANKL-induced intracellular signaling pathways","volume":"237","author":"G Wang","year":"2022","journal-title":"J Cell Physiol"},{"key":"pone.0359087.ref017","doi-asserted-by":"crossref","first-page":"1449143","DOI":"10.3389\/fonc.2024.1449143","article-title":"Roburic acid inhibits lung cancer metastasis and triggers autophagy as verified by network pharmacology, molecular docking techniques and experiments","volume":"14","author":"L Wang","year":"2024","journal-title":"Front Oncol"},{"issue":"1","key":"pone.0359087.ref018","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1080\/14756366.2021.2018684","article-title":"Inhibitory effect of roburic acid in combination with docetaxel on human prostate cancer cells","volume":"37","author":"X Wang","year":"2022","journal-title":"J Enzyme Inhib Med Chem"},{"key":"pone.0359087.ref019","doi-asserted-by":"crossref","first-page":"853165","DOI":"10.3389\/fimmu.2022.853165","article-title":"Roburic acid targets TNF to Inhibit the NF-\u03baB signaling pathway and suppress human colorectal cancer cell growth","volume":"13","author":"H Xu","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"pone.0359087.ref020","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/nrg2918","article-title":"Network medicine: A network-based approach to human disease","volume":"12","author":"A-L Barab\u00e1si","year":"2011","journal-title":"Nat Rev Genet"},{"issue":"2","key":"pone.0359087.ref021","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.tips.2021.11.004","article-title":"Network pharmacology: curing causal mechanisms instead of treating symptoms","volume":"43","author":"C Nogales","year":"2022","journal-title":"Trends Pharmacol Sci"},{"issue":"4","key":"pone.0359087.ref022","first-page":"192","article-title":"Integrating network pharmacology and experimental validation to explore the potential mechanism by which resveratrol acts on osimertinib resistance in lung cancer","volume":"29","author":"X Yu","year":"2025","journal-title":"Oncol Lett"},{"issue":"10","key":"pone.0359087.ref023","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1038\/nbt1338","article-title":"Drug-target network","volume":"25","author":"MA Yildirim","year":"2007","journal-title":"Nat Biotechnol"},{"issue":"7","key":"pone.0359087.ref024","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/nmeth.3440","article-title":"Pathway and network analysis of cancer genomes","volume":"12","author":"P Creixell","year":"2015","journal-title":"Nat Methods"},{"issue":"8","key":"pone.0359087.ref025","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1039\/C5NP00005J","article-title":"Network pharmacology applications to map the unexplored target space and therapeutic potential of natural products","volume":"32","author":"M Kibble","year":"2015","journal-title":"Nat Prod Rep"},{"issue":"5","key":"pone.0359087.ref026","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1039\/C3MB70507B","article-title":"A novel network pharmacology approach to analyse traditional herbal formulae: the Liu-Wei-Di-Huang pill as a case study","volume":"10","author":"X Liang","year":"2014","journal-title":"Mol Biosyst"},{"issue":"1","key":"pone.0359087.ref027","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jep.2012.09.051","article-title":"Network pharmacology-based prediction of the active ingredients and potential targets of Chinese herbal Radix Curcumae formula for application to cardiovascular disease","volume":"145","author":"W Tao","year":"2013","journal-title":"J Ethnopharmacol"},{"issue":"1","key":"pone.0359087.ref028","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbad518","article-title":"Network pharmacology: towards the artificial intelligence-based precision traditional Chinese medicine","volume":"25","author":"P Zhang","year":"2023","journal-title":"Brief Bioinform"},{"issue":"5","key":"pone.0359087.ref029","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1002503","article-title":"Prediction of drug-target interactions and drug repositioning via network-based inference","volume":"8","author":"F Cheng","year":"2012","journal-title":"PLoS Comput Biol"},{"issue":"7","key":"pone.0359087.ref030","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/nbt.2284","article-title":"Combinatorial drug therapy for cancer in the post-genomic era","volume":"30","author":"B Al-Lazikani","year":"2012","journal-title":"Nat Biotechnol"},{"issue":"11","key":"pone.0359087.ref031","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nchembio.118","article-title":"Network pharmacology: the next paradigm in drug discovery","volume":"4","author":"AL Hopkins","year":"2008","journal-title":"Nat Chem Biol"},{"issue":"1","key":"pone.0359087.ref032","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s11154-023-09833-1","article-title":"Advances in the management of anaplastic thyroid carcinoma: Transforming a life-threatening condition into a potentially treatable disease","volume":"25","author":"I Califano","year":"2024","journal-title":"Rev Endocr Metab Disord"},{"key":"pone.0359087.ref033","doi-asserted-by":"crossref","first-page":"1103147","DOI":"10.3389\/fonc.2023.1103147","article-title":"Immunotherapy or targeted therapy: What will be the future treatment for anaplastic thyroid carcinoma?","volume":"13","author":"X Gao","year":"2023","journal-title":"Front Oncol"},{"issue":"6","key":"pone.0359087.ref034","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41573-019-0024-5","article-title":"Applications of machine learning in drug discovery and development","volume":"18","author":"J Vamathevan","year":"2019","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"pone.0359087.ref035","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1124\/pr.112.007336","article-title":"Computational methods in drug discovery","volume":"66","author":"G Sliwoski","year":"2013","journal-title":"Pharmacol Rev"},{"issue":"4","key":"pone.0359087.ref036","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1152\/physrev.00046.2011","article-title":"Stem cell factor receptor\/c-Kit: From basic science to clinical implications","volume":"92","author":"J Lennartsson","year":"2012","journal-title":"Physiol Rev"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0359087","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:29:56Z","timestamp":1792085396000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0359087"}},"subtitle":[],"editor":[{"given":"James","family":"Guevara Pulido","sequence":"first","affiliation":[{"name":"Universidad El Bosque","place":["COLOMBIA"]}],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,10,15]]},"references-count":36,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10,15]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0359087","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,15]]}}}